Selank: What the Anxiolytic Peptide Research Actually Shows

What is Selank?

Selank is a synthetic peptide of seven amino acids: Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its front half is a copy of tuftsin, a natural four-amino-acid peptide (Thr-Lys-Pro-Arg) that the immune system produces from an antibody fragment. The extra Pro-Gly-Pro tail was added for one practical reason: tuftsin on its own is broken down almost instantly in the body, and the tail makes the molecule more stable. So Selank is best understood as a stabilized, longer-acting relative of an immune peptide, repurposed for the brain.

It was developed in Russia at the Institute of Molecular Genetics together with the Zakusov Institute of Pharmacology, part of the same peptide-research program that produced the nootropic peptide Semax. Both are given as nasal drops, both come from that Moscow lineage, and both are far better known in Russia than anywhere else.

The reason Selank is delivered up the nose rather than swallowed is not marketing. Peptides are digested like any other protein, and oral bioavailability for small peptides is generally very poor, which is a well-documented barrier in peptide drug development (PubMed 15984901). The intranasal route is an attempt to get past the gut and reach the circulation, and possibly the brain, more directly.

How does Selank work? GABA, serotonin, BDNF and enkephalins

Selank does not act on a single named receptor the way a benzodiazepine sits on the GABA-A receptor. Its proposed mechanism is a spread of downstream effects across several neurochemical systems, which is both what makes it interesting and what makes it hard to pin down. A 2018 review in the International Journal of Molecular Sciences collected the molecular evidence and describes actions touching GABAergic, serotonergic, dopaminergic and monoamine pathways, along with effects on the expression of genes tied to immunity and inflammation (PubMed 30255741).

Three strands of that mechanism are worth separating out.

Enkephalin protection. One of the earliest and most specific findings is that Selank inhibits the enzymes that break down enkephalins, the body's own opioid-like signaling peptides. In human plasma it blocked enkephalin degradation with a measured potency (IC50 around 15 micromolar) greater than reference peptidase inhibitors, and the authors proposed this as a route to its anti-anxiety effect (PubMed 11550013). By slowing their breakdown, Selank could raise the effective level of these calming peptides.

BDNF. Brain-derived neurotrophic factor supports the survival and plasticity of neurons and is repeatedly linked to mood regulation. In rats, intranasal Selank raised BDNF messenger RNA in the hippocampus within roughly three hours and BDNF protein within 24 hours (PubMed 18841804). That is a concrete, same-day molecular change in a brain region central to stress and memory.

Serotonin and immune-gene signaling. Because Selank descends from an immune peptide, several studies look at inflammation rather than mood. In mouse spleen, Selank altered the expression of inflammation-related genes, consistent with tuftsin's immunomodulatory heritage (PubMed 21609736). Reviews tie this to the serotonin system as well, since immune signaling and serotonin metabolism overlap. The honest summary is that Selank nudges several systems at once, and no one has cleanly shown which change actually produces the calming effect.

Does Selank actually work for anxiety?

This needs two answers, because the animal evidence and the human evidence sit at different levels of confidence.

In animals, the anxiolytic signal is fairly consistent. Rodent models of anxiety respond to Selank with reduced fear-type behavior, and the effect has been reproduced across several study designs. In one unpredictable chronic mild stress model, Selank not only reduced anxiety-linked behavior on its own but enhanced the effect of diazepam, a standard benzodiazepine, when the two were combined (PubMed 28280289). Separate work reports that Selank can also improve learning and memory endpoints in animals, which is where the "nootropic" label comes from (PubMed 20919548).

In humans, the picture is thinner and comes almost entirely from Russia. An open clinical study reported that Selank produced anxiolytic and anti-asthenic effects in patients with generalized anxiety disorder and neurasthenia, with the authors judging its efficacy broadly comparable to standard anxiolytics (PubMed 18454096). That is a real, peer-reviewed clinical result, and it should be read with its limits attached: the human trials are small, most originate from the same research group that developed the compound, and few are double-blind or placebo-controlled. That combination is exactly the setup where early enthusiasm often shrinks once larger independent trials are run. As with other Russian peptides such as Semax, the domestic evidence is genuine but has never been confirmed by the large Western trials that regulators rely on.

Selank vs benzodiazepines: what the comparison studies found

The single most cited reason people look at Selank is the claim that it matches a benzodiazepine for anxiety without the downsides. That claim traces to a specific comparison. In a Russian study, Selank was measured head-to-head against phenazepam, a benzodiazepine used widely in Russia, and the authors reported comparable anxiolytic effect with better tolerability — notably without the sedation and without the dependence pattern that define the drug class (PubMed 25176261).

Taken at face value, that is an appealing profile. Benzodiazepines work fast and reliably, but tolerance, dependence, withdrawal, sedation, and impaired memory are well-established problems with them. A drug that quieted anxiety while avoiding those hazards would be genuinely useful. The reason to stay cautious is not the mechanism, which is plausible, but the strength of the evidence: a small number of short trials, largely from one group, is a fragile foundation for a claim of equivalence to one of the most-studied drug classes in medicine.

The table makes the trade-off explicit. Benzodiazepines have a heavy side-effect burden but an enormous, independent evidence base. Selank has a gentler reported profile but a small and largely self-contained one. "Comparable in a small trial" and "proven equivalent" are different statements, and the gap between them is the whole story.

Is Selank FDA approved or legal?

Selank is not approved by the US Food and Drug Administration for anxiety or anything else. There is no prescription Selank in the United States, and it has not been evaluated in the large placebo-controlled trials the FDA requires before approving a psychiatric drug. Its regulatory home is Russia, where it is registered as an anxiolytic. A foreign registration is meaningful context, but it is not FDA approval and should not be read as one.

Legally, Selank sits in the unapproved research-chemical category in most Western markets. It is not a scheduled controlled substance, so possession is not a drug-crime issue in the way an illegal narcotic would be, but it is also not an approved medicine or a lawful dietary supplement, which means it cannot be marketed for human use. Product sold online as an intranasal solution is not manufactured to pharmaceutical standards and its purity is not independently verified. Our overview of peptide legality and regulatory status walks through how this "approved somewhere, unapproved here" pattern applies across compounds, including how the FDA has treated peptides in compounding.

Selank side effects reported in studies

The reported safety profile is one of Selank's strongest talking points, and also one of its most over-read. In the short studies published, adverse effects were mild and mostly local: irritation of the nasal lining from the intranasal route, occasional headache, and some reports of fatigue. The trials did not report the sedation, cognitive impairment, dependence, or withdrawal seen with benzodiazepines (PubMed 25176261).

Two caveats keep that from being a clean bill of health. First, the studies are short and small. A few weeks of observation in a modest number of people cannot characterize rare adverse events, drug interactions, or what happens with months or years of use. Absence of reported harm in that setting is weak evidence of long-term safety, not strong evidence. Second, most of the safety data describe pharmaceutical-grade material used under study conditions. Research-chemical vials sold for self-administration are a different product, with unverified purity and no guarantee of sterile handling — a hazard separate from the molecule itself.

There is also a mechanistic reason to stay humble. Selank touches immune-gene expression and several neurotransmitter systems at once (PubMed 30255741). Broad, multi-system activity is precisely the kind of profile where subtle long-term effects can hide, and where a larger, longer trial would be most valuable.

Selank vs Semax: what's the difference?

Selank and Semax are constantly mentioned together, and for good reason: same country, same research institutes, same intranasal delivery, same status as compounds famous in Russia and largely unstudied in large Western trials. But they are not interchangeable.

Selank comes from tuftsin, an immune peptide, and is framed primarily as an anxiolytic — its headline use is calming anxiety. Semax comes from a fragment of adrenocorticotropic hormone, ACTH(4-10), and is framed as a nootropic and neuroprotective agent, studied in contexts like cognitive performance and ischemic stroke (PubMed 16996699). Their effects overlap — Selank has cognitive data and Semax has mood data — but the center of gravity differs: Selank for anxiety, Semax for focus. Neither is FDA approved, and both share the same limitation of a Russia-centric evidence base.

If your interest is the wider world of peptides marketed for the brain, longevity and cellular health, it is worth reading these compounds side by side rather than in isolation — see our summaries of epitalon and the telomere claims, the mitochondrial peptide MOTS-c, and NAD+ and its precursors, all of which share Selank's core problem of interesting mechanisms running ahead of human proof.

How long does Selank take to work?

Selank is generally described as fast-acting, and the molecular data are consistent with that. If a single intranasal dose can shift hippocampal BDNF within hours (PubMed 18841804), a same-day change in subjective calm is at least biologically plausible, and users commonly report exactly that. The peptide itself is cleared quickly, which is one reason it is dosed as a short course rather than a single event.

For a sustained anxiety benefit, the human studies observed patients over courses of roughly two weeks before judging improvement (PubMed 18454096). What does not exist is a reliable answer to the longer question — how durable any benefit is, or whether effects hold up over months — because the long-term controlled trials that would settle it have not been published. Anyone comparing Selank against an established anxiety treatment is comparing a two-week Russian dataset against drugs with years of follow-up.

That uncertainty is the practical case for keeping a record. Anxiety fluctuates on its own, expectation effects are powerful with a compound this hyped, and it is easy to credit a peptide for a good week that would have happened anyway. A dated log of what was taken and how you felt is the only way to separate a real signal from a hopeful one.

Frequently asked questions

Sources

Every claim above traces to peer-reviewed literature indexed on PubMed:

1. The Molecular Aspects of Heptapeptide Selank Biological Activity — PubMed 30255741
2. A comparison of the anxiolytic effect and tolerability of Selank and phenazepam — PubMed 25176261
3. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity — PubMed 11550013
4. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo — PubMed 18841804
5. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats — PubMed 28280289
6. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia — PubMed 18454096
7. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank — PubMed 21609736
8. Experimental optimization of learning and memory processes by selank — PubMed 20919548
9. Semax, an analogue of adrenocorticotropin (4-10): experimental study of its neuroprotective properties — PubMed 16996699
10. Oral delivery of peptide drugs: barriers and developments — PubMed 15984901
11. Biochemistry, Peptide — PubMed 32965931

Keep reading